Do We have a Satisfactory Cell Viability Assay? Review of the Currently Commercially-Available Assays

Author:

Halim Abdel-Baset1

Affiliation:

1. VP Translational Medicine, Biomarkers & Diagnostics, Celldex Therapeutics, 53 Frontage Road, Suite 220, Hampton, NJ 08827-4032, United States

Abstract

:Cell-based assays are an important part of the drug discovery process and clinical research. One of the main hurdles is to design sufficiently robust assays with adequate signal to noise parameters while maintaining the inherent physiology of the cells and not interfering with the pharmacology of target being investigated.:A plethora of assays that assess cell viability (or cell heath in general) are commercially available and can be classified under different categories according to their concepts and principle of reactions. The assays are valuable tools, however, suffer from a large number of limitations. Some of these limitations can be procedural or operational, but others can be critical as those related to a poor concept or the lack of proof of concept of an assay, e.g. those relying on differential permeability of dyes in-and-out of viable versus compromised cell membranes. While the assays can differentiate between dead and live cells, most, if not all, of them can just assess the relative performance of cells rather than providing a clear distinction between healthy and dying cells. The possible impact of relatively high molecular weight dyes, used in most of the assay, on cell viability has not been addressed. More innovative assays are needed, and until better alternatives are developed, setup of current cell-based studies and data interpretation should be made with the limitations in mind. Negative and positive control should be considered whenever feasible. Also, researchers should use more than one orthogonal method for better assessment of cell health.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery

Reference75 articles.

1. Iorio F.; Knijnenburg T.A.; Vis D.J.; Bignell G.R.; Menden M.P.; Schubert M.; Aben N.; Gonçalves E.; Barthorpe S.; Lightfoot H.; Cokelaer T.; Greninger P.; van Dyk E.; Chang H.; de Silva H.; Heyn H.; Deng X.; Egan R.K.; Liu Q.; Mironenko T.; Mitropoulos X.; Richardson L.; Wang J.; Zhang T.; Moran S.; Sayols S.; Soleimani M.; Tamborero D.; Lopez-Bigas N.; Ross-Macdonald P.; Esteller M.; Gray N.S.; Haber D.A.; Stratton M.R.; Benes C.H.; Wessels L.F.A.; Saez-Rodriguez J.; McDermott U.; Garnett M.J.; A Landscape of pharmacogenomic interactions in cancer. Cell 2016,166(3),740-754

2. Thomas D.W.; Burns J.; Audette J.; Carroll A.; Dow-Hygelund C.; Hay M.; Clinical Development Success Rates 2006-2015 - BIO, Biomedtracker, Amplion 2016. Available at : https: //www.bio.org/sites/default/files/Clinical%20 Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf

3. Barretina J.; Caponigro G.; Stransky N.; Venkatesan K.; Margolin A.A.; Kim S.; Wilson C.J.; Lehár J.; Kryukov G.V.; Sonkin D.; Reddy A.; Liu M.; Murray L.; Berger M.F.; Monahan J.E.; Morais P.; Meltzer J.; Korejwa A.; Jané-Valbuena J.; Mapa F.A.; Thibault J.; Bric-Furlong E.; Raman P.; Shipway A.; Engels I.H.; Cheng J.; Yu G.K.; Yu J.; Aspesi P.; de Silva M.; Jagtap K.; Jones M.D.; Wang L.; Hatton C.; Palescandolo E.; Gupta S.; Mahan S.; Sougnez C.; Onofrio R.C.; Liefeld T.; MacConaill L.; Winckler W.; Reich M.; Li N.; Mesirov J.P.; Gabriel S.B.; Getz G.; Ardlie K.; Chan V.; Myer V.E.; Weber B.L.; Porter J.; Warmuth M.; Finan P.; Harris J.L.; Meyerson M.; Golub T.R.; Morrissey M.P.; Sellers W.R.; Schlegel R.; Garraway L.A.; The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012,483(7391),603-607

4. Fox J.T.; Myung K.; Cell-based high-throughput screens for the discovery of chemotherapeutic agents. Oncotarget 2012,3(5),581-585

5. Nichols A.C.; Black M.; Yoo J.; Pinto N.; Fernandes A.; Haibe-Kains B.; Boutros P.C.; Barrett J.W.; Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer. BMC Pharmacol Toxicol 2014,15,66

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3